George Lundberg, MD Editor in Chief at Cancer Commons
-
December 13, 2019
Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections Bookmark
George Lundberg, MDResearch paper from the Archives of Pathology & Laboratory Medicine curated by Editor in Chief George Lundberg, MD, who notes:
Plasmacytoid urothelial carcinoma merits special aggressive therapy.
Go to full paper published in the Archives of Pathology & Laboratory Medicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
Cervical Cancer – Overview Bookmark
George Lundberg, MDCurated by Editor in Chief George Lundberg, MD, who notes:
The third leading cause of cancer death of women in developing countries, advanced cervical cancer is relatively rare in the U.S. This comprehensive review summarizes it nicely.
.
-
December 13, 2019
Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-Blind, Phase 3 Trial Bookmark
George Lundberg, MDResearch paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes:
A drug called Cyramza improves progession-free survival (PFS) but not overall survival (OS) of patients with advanced bladder cancer in a phase lll clinical trial.
Go to full paper published in The Lancet.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
PARP Inhibitors Center Stage for Ovarian Cancer Bookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
A Virtual Molecular Tumor Board to Improve Efficiency and Scalability of Delivering Precision Oncology to Physicians and Their Patients Bookmark
George Lundberg, MDResearch paper from JAMIA Open curated by Editor in Chief George Lundberg, MD, who notes:
This study found a virtual molecular tumor board to be efficient and effective for more than 1,000 patients.
Go to full paper published in JAMIA Open.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysis Bookmark
George Lundberg, MDResearch paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes:
This meta-analysis found that minimally invasive surgery tops open esophagectomy for esophageal cancer.
Go to full paper published in Annals of Surgery.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Chemotherapy alone bests cytoreductive surgery plus chemotherapy in recurrent ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement Bookmark
George Lundberg, MDResearch paper from The Journal of the American Medical Association (JAMA) curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Preventive Services Task Force recommends against screening for pancreatic cancer in asymptomatic adults.
Go to full paper published in JAMA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.